HiloProbe has raised an additional 3 million kronor in funding from existing owners. This capital injection is a step towards achieving the next goal. ”The main focus of this capital injection is to initiate sales, which will enable us to attract a larger amount of...

Swedish biotech company HiloProbe says it has reached a significant milestone after the results of a prospective multicenter study conducted in collaboration with Umeå University and eight Swedish hospitals were published in the International Journal of Cancer. The...

Thomas Busch has taken over as Chairman of the Board at Swedish biotech company Hiloprobe AB at what he calls “an exciting time” for the thriving business. “We are now ready to transition from a research company to actively marketing and selling our ColoNode biomarker...

Umeå University, has in collaboration with HiloProbe AB completed the first part of a new clinical study of its ColoNode biomarker test, which provides further important evidence for the product ColoNode's benefits and usefulness in colon cancer. “The results look...

We are very happy to start a collaboration and a long-term relationship with Biocartis, which strengthens our focus on colorectal cancer thanks to Biocartis’ established sales and distribution network across many countries. For more information please read Biocartis...

HiloProbe has participated in a major international surgeon congress in Dublin. - Surgeons are one of our main stakeholders and therefore it important to meet, discuss and present data to them, says Lina Olsson, CEO. HiloProbe participated at the well-attended ESCP...

HiloProbe has CE-marked the ColoNode to satisfy the needs of potential customers who want to start testing the product. - Research Use Only was not enough. Therefore, we have put a lot of focus and resources into completing CE documentation according to IVDD in order...

Den 6 oktober deltog Hiloprobe på Cancerdagen. Här kan du se hela föreläsningen. Det var Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, som på Cancerdagen talade om ett nytt lymfkörteltest för stadieindelning och...

Hiloprobe deltar på Cancerdagen den 6 oktober för att presentera de nya möjligheter som deras diagnostik-kit Colonode kan ge för behandling av kolorektalcancer. Marie-Louise Hammarström, professor vid institutionen för klinisk mikrobiologi, Umeå universitet, ska tala...

HiloProbe has been granted SEK 2 million from Swedish Innovation Agency Vinnova to validate a product that detects and helps treat people with colorectal cancer. “This is an important grant for us and means we can validate our product and make it available to the...